| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028468472 |
| P356 | DOI | 10.1186/1471-2180-8-39 |
| P932 | PMC publication ID | 2289824 |
| P698 | PubMed publication ID | 18304359 |
| P5875 | ResearchGate publication ID | 5548831 |
| P50 | author | Timothy Stinear | Q30347065 |
| Ashley Mansell | Q37376445 | ||
| Benjamin P. Howden | Q37837894 | ||
| P2093 | author name string | John K Davies | |
| Paul D R Johnson | |||
| Peter B Ward | |||
| Danielle J Smith | |||
| P2860 | cites work | Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state | Q24291852 |
| Recognition of Staphylococcus aureus by the innate immune system | Q24530569 | ||
| BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. | Q24792694 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| Inhibition of rot translation by RNAIII, a key feature of agr function | Q28255084 | ||
| Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1 | Q28271523 | ||
| TM4: a free, open-source system for microarray data management and analysis | Q29547339 | ||
| Global regulation of Staphylococcus aureus genes by Rot | Q31123861 | ||
| DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. | Q33220466 | ||
| Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. | Q33264418 | ||
| Antimicrobial peptides from platelets | Q33338526 | ||
| Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function | Q33883752 | ||
| Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. | Q33959130 | ||
| Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates | Q33978642 | ||
| Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds | Q33978671 | ||
| Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets | Q34003911 | ||
| Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 | ||
| Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. | Q34116833 | ||
| Transcription Profiling of the mgrA Regulon in Staphylococcus aureus | Q34509922 | ||
| Coordinated and differential control of aureolysin (aur) and serine protease (sspA) transcription in Staphylococcus aureus by sarA, rot and agr (RNAIII). | Q34539527 | ||
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
| Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing | Q34630593 | ||
| In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance | Q34721614 | ||
| Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus | Q34747322 | ||
| The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. | Q34762753 | ||
| Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin | Q34823746 | ||
| Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia | Q35023343 | ||
| Mgr, a novel global regulator in Staphylococcus aureus | Q35098154 | ||
| Staphylococcus aureus capsular polysaccharides | Q35630504 | ||
| Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002 | Q35872823 | ||
| Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. | Q36025384 | ||
| Vancomycin-resistant staphylococci and enterococci: epidemiology and control | Q36178104 | ||
| Complement-dependent platelet injury by staphylococcal protein A | Q36271673 | ||
| The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q36381504 | ||
| The interaction of bacterial pathogens with platelets | Q36482515 | ||
| Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus | Q36670735 | ||
| Variation in the expression of cell wall proteins of Staphylococcus aureus grown on solid and liquid media | Q37003585 | ||
| Extensive and genome-wide changes in the transcription profile of Staphylococcus aureus induced by modulating the transcription of the cell wall synthesis gene murF. | Q38306144 | ||
| Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method | Q38314636 | ||
| Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus | Q38352516 | ||
| Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. | Q39474811 | ||
| An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states | Q39632724 | ||
| Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus | Q40345457 | ||
| Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin | Q41867637 | ||
| Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation | Q42112243 | ||
| Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. | Q42112516 | ||
| Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions | Q42181494 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| Purification and characterization of urease from Helicobacter pylori | Q43729113 | ||
| Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon | Q44605321 | ||
| Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein | Q45023859 | ||
| Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia | Q46933141 | ||
| Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus | Q57614225 | ||
| Expression of staphylococcal protein Sbi is induced by human IgG | Q73920116 | ||
| Genetic analysis of the cap5 locus of Staphylococcus aureus | Q77908317 | ||
| Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets | Q80805583 | ||
| Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils | Q81180246 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| bacterial evolution | Q115395667 | ||
| P304 | page(s) | 39 | |
| P577 | publication date | 2008-02-27 | |
| P1433 | published in | BMC Microbiology | Q15759430 |
| P1476 | title | Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia | |
| P478 | volume | 8 |
| Q30455758 | A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin |
| Q64263426 | Absence of Protein A Expression Is Associated With Higher Capsule Production in Staphylococcal Isolates |
| Q98665067 | Acapsular Staphylococcus aureus with a non-functional agr regains capsule expression after passage through the bloodstream in a bacteremia mouse model |
| Q37277083 | Acquired vancomycin resistance in clinically relevant pathogens |
| Q34648042 | Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies |
| Q36882486 | Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus |
| Q35745676 | An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection |
| Q24596120 | Analysis of the small RNA transcriptional response in multidrug-resistant Staphylococcus aureus after antimicrobial exposure |
| Q34057548 | Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus |
| Q37124131 | Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection |
| Q38425879 | Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus |
| Q30401758 | Coagulase-negative staphylococci. |
| Q36964857 | Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains |
| Q36969754 | Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression |
| Q92003682 | Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms |
| Q35432686 | Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections |
| Q39555150 | Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. |
| Q28477900 | Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR |
| Q33501860 | Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-alpha and NF-kappab are key components of the innate immune response to the pathogen |
| Q42782239 | Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. |
| Q35728976 | Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. |
| Q36932920 | Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus |
| Q37717901 | Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance |
| Q36589269 | Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis |
| Q38958136 | Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia |
| Q39218893 | Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria |
| Q35105880 | Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant Staphylococcus aureus strain MW2 |
| Q50132676 | Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility |
| Q90700039 | Methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in Taiwan |
| Q33500363 | Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients |
| Q49453092 | Mutation of Agr Is Associated with the Adaptation of Staphylococcus aureus to the Host during Chronic Osteomyelitis |
| Q37575024 | Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus |
| Q41776452 | Population Genomics of Reduced Vancomycin Susceptibility in Staphylococcus aureus. |
| Q34632683 | Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility |
| Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
| Q36644897 | Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. |
| Q36153912 | Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus |
| Q46236730 | Severe infections emerge from commensal bacteria by adaptive evolution |
| Q37809666 | Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates |
| Q94566860 | The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications |
| Q42914487 | Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria |
| Q33604815 | Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection |
| Q34108614 | Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. |
| Q95355781 | Vancomycin Resistance in Staphylococcus aureus |
| Q33945397 | Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. |
| Q37236231 | Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system |
| Q42280738 | Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression |
| Q42358800 | VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA. |
| Q51247058 | WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108. |
| Q28478770 | Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus |
Search more.